Sutro Biopharma Inc. (STRO) is a clinical-stage biotechnology company that develops next-generation antibody-drug conjugate (ADC) therapies for the treatment of cancer and other diseases. The company's proprietary XpressCF+ platform enables the rapid and efficient discovery, development, and manufacturing of high-quality, homogeneous ADCs. STRO's lead product candidate, STRO-002, is an ADC targeting folate receptor alpha that is currently in Phase 1 clinical trials for the treatment of ovarian and endometrial cancers. The company is also developing several other ADCs, including STRO-001, which targets CD74 and is in Phase 1 clinical trials for the treatment of multiple myeloma and lymphoma. Sutro Biopharma is headquartered in South San Francisco, California. As of September 2021, the company had a market capitalization of approximately $1.07 billion.
Sutro Biopharma Inc. (STRO) is a clinical-stage biotechnology company that develops next-generation antibody-drug conjugate (ADC) therapies for the treatment of cancer and other diseases. The company's proprietary XpressCF+ platform enables the rapid and efficient discovery, development, and manufacturing of high-quality, homogeneous ADCs. STRO's lead product candidate, STRO-002, is an ADC targeting folate receptor alpha that is currently in Phase 1 clinical trials for the treatment of ovarian and endometrial cancers. The company is also developing several other ADCs, including STRO-001, which targets CD74 and is in Phase 1 clinical trials for the treatment of multiple myeloma and lymphoma. Sutro Biopharma is headquartered in South San Francisco, California. As of September 2021, the company had a market capitalization of approximately $1.07 billion.